16 Nov 2019The Medicines Company Announces that the ORION-10 Study of Inclisiran in ASCVD Patients Showed Durable and Potent Lowering of LDL-C with Twice-Yearly Dosing
(World News USA)

- Inclisiran achieved 58% LDL-C lowering with time-adjusted reductions of 56% sustained over 18 months of treatment in patients with atherosclerotic cardiovascular disease (ASCVD) - ORION-10 study affirmed inclisiran`s excellent safety profile, including no treatment-related liver or renal abnormalities - Results presented today during late-breaking science session at American Heart Association annual meeting in Philadelphia - The Medicines Company to host investor conference call and webcast on Monday, November 18, 12:00 pm EST The Medicines Company (NASDAQ: MDCO) today announced detailed results from ORION-10, the second of three pivotal 18-month low-density lipoprotein cholesterol (LDL-C)...